Evidence map›Paper›PMID 33800939›Full record

ArticleJournal of personalized medicine2021

The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up.

Adam Kern, Tomasz Stompór, Jolanta Kiewisz, Bartłomiej E Kraziński, Jacek Kiezun, Marta Kiezun, Jerzy Górny, Ewa Sienkiewicz, Leszek Gromadziński, Dariusz Onichimowski and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Adam KernDepartment of Cardiology and Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.ORCID 0000-0003-3341-3701
Tomasz StompórDepartment of Nephrology, Hypertension and Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
Jolanta KiewiszDepartment of Human Histology and Embryology, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
Bartłomiej E KrazińskiDepartment of Human Histology and Embryology, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.ORCID 0000-0002-3537-4710
Jacek KiezunDepartment of Human Histology and Embryology, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.
Marta KiezunDepartment of Animal Anatomy and Physiology, Faculty of Biology and Biotechnology, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.ORCID 0000-0002-8677-5282
Jerzy GórnyDepartment of Cardiology, Voivodal Specialist Hospital in Olsztyn, 10-561 Olsztyn, Poland.
Ewa SienkiewiczDepartment of Cardiology, Voivodal Specialist Hospital in Olsztyn, 10-561 Olsztyn, Poland.
Leszek GromadzińskiDepartment of Cardiology and Internal Medicine, Medical Faculty, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland.ORCID 0000-0002-8827-4203
Dariusz OnichimowskiDepartment of Anaesthesiology and Intensive Care, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, 10-561 Olsztyn, Poland.
Jacek BilDepartment of Invasive Cardiology, Centre of Postgraduate Medical Education, 02-507 Warsaw, Poland.ORCID 0000-0002-8724-5611
University of Warmia and Mazury in Olsztyn · PLUniversity of Computer Sciences and Economics in Olsztyn · PLPostgraduate School of Molecular Medicine · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sclerostin might play a role in atherosclerosis development. This study aimed to analyze the impact of baseline sclerostin levels on 9-year outcomes in patients without significant renal function impairment and undergoing coronary angiography. The primary study endpoint was the rate of major cardiovascular events (MACE), defined as a combined rate of myocardial infarction (MI), stroke, or death at 9 years. We included 205 patients with a mean age of 62.9 ± 0.6 years and 70.2% male. Median serum sclerostin concentration was 133.22 pg/mL (IQR 64.0-276.17). At 9 years, in the whole population, the rate of MACE was 34.1% (

Indexed as

bone metabolismcardiovascular eventscoronary angiographycoronary artery diseasedeathKlothomultivessel diseasemyocardial infarctionosteocytesclerostinstroke

Identifiers

PMID33800939
PMCPMC8001826
OpenAlexW3135200902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.